Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04947124 · ClinicalTrials.gov registry record · Phase 2
A Study to Determine the Safety and Tolerability of 2 Concentrations of QLS-101
A Phase 2 study, sponsored by Qlaris Bio.
- Completed
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT04947124: Completed Phase 2 study, sponsored by Qlaris Bio.
NCT04947124 is a Phase 2 study that has completed, run by Qlaris Bio. The registered enrollment target is 3 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04947124, a Phase 2 study, has completed, sponsored by Qlaris Bio.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
Safety and tolerability study of 2 concentrations of QLS-101 for adult subjects with Sturge Weber Syndrome (SWS)-related glaucoma due to elevated episcleral venous pressure (EVP).
Primary Outcome
Standard safety endpoint, ocular AEs, (including elevated IOP)
Interventions
- DRUG QLS-101ophthalmic solution 1%
- DRUG QLS-101ophthalmic solution 2%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2021-10-19 |
| Est. Completion | 2022-08-01 |
| Phase | Phase 2 |
What the finished NCT04947124 record still lists
NCT04947124 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 2 interventions - of which QLS-101ophthalmic solution 1% is the first listed.
NCT04947124 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04947124 about?
NCT04947124 is a clinical study titled "A Study to Determine the Safety and Tolerability of 2 Concentrations of QLS-101". Safety and tolerability study of 2 concentrations of QLS-101 for adult subjects with Sturge Weber Syndrome (SWS)-related glaucoma due to elevated episcleral venous pressure (EVP).
What is the current status of trial NCT04947124?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2021-10-19. Estimated completion is 2022-08-01.
What interventions are being tested in trial NCT04947124?
The interventions under investigation include: QLS-101ophthalmic solution 1% (DRUG), QLS-101ophthalmic solution 2% (DRUG).
Who is sponsoring clinical trial NCT04947124?
This trial is sponsored by Qlaris Bio, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04947124's enrollment target sits among peer trials
3 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI